最新動態
概要
2019年6月3日
公司命名變更

本公司的英文名稱已由 "New B Innovation Limited" 變更為 "New Beta Innovation Limited",自二零一九年六月三日起生效。此外,公司的中文名稱 "新行健醫藥科技有限公司" 則維持不變。

請知悉是次命名變更是不會影響公司架構以及本公司對外已簽署的合同及協議書。

2019年1月11日
Commencement of FiH Healthy Volunteer Study

The First-in-Human (FiH) healthy volunteer study to evaluate safety on the use of YQ23 has commenced on 11 Jan 2019. This study is mainly to assess the safety, tolerability and pharmacokinetics (PK - the amount of study drug in the blood) of ascending single dose of YQ23 in healthy male and female subjects. The clinical trial is conducted at a Phase 1 centre in UK and will enroll approximately 40 subjects.

2016年7月11日
Approval of Clinical Trial Application in HK

New Beta Innovation receives approval from the Hong Kong Department of Health (DoH) to proceed with a Phase 1 Clinical Trial (First-in-Patient) of YQ23 in patients with advanced tumors.

2016年3月21日
EMA Orphan Medicinal Product Designation

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

2015年10月13日
Approval of Clinical Trial Application in UK

New Beta Innovation receives UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to proceed with a Phase 1 Clinical Trial (First-in-Human) of YQ23 in healthy volunteers.

2014年11月19日
EMA Orphan Medicinal Product Designation

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

× 我們使用網站信標(page tagging)及小型文字檔案(cookies)來改進網站及為您提供最佳的網站服務與體驗。如果您繼續瀏覽本網站,即表示您接受我們使用小型文字檔案(cookies)。